Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19

Chia Siang Kow; Mamoon Aldeyab; Syed Shahzad Hasan

doi:10.1007/s00228-020-03008-6

Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19

Chia Siang Kow, Mamoon Aldeyab, Syed Shahzad Hasan

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	435-437
Number of pages	3
Journal	European Journal of Clinical Pharmacology
Volume	77
Issue number	3
Early online date	4 Oct 2020
DOIs	https://doi.org/10.1007/s00228-020-03008-6
Publication status	Published - 1 Mar 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/s00228-020-03008-6Licence: Unspecified

Cite this

@article{a717875ff62b42f19075b5ca9321756f,

title = "Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19",

keywords = "COVID-19, Clinical trials, remdesivir",

author = "Kow, \{Chia Siang\} and Mamoon Aldeyab and Hasan, \{Syed Shahzad\}",

year = "2021",

month = mar,

day = "1",

doi = "10.1007/s00228-020-03008-6",

language = "English",

volume = "77",

pages = "435--437",

journal = "European Journal of Clinical Pharmacology",

issn = "0031-6970",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "3",

}

TY - JOUR

T1 - Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19

AU - Kow, Chia Siang

AU - Aldeyab, Mamoon

AU - Hasan, Syed Shahzad

PY - 2021/3/1

Y1 - 2021/3/1

KW - COVID-19

KW - Clinical trials

KW - remdesivir

UR - https://www.scopus.com/pages/publications/85091851173

U2 - 10.1007/s00228-020-03008-6

DO - 10.1007/s00228-020-03008-6

M3 - Letter

C2 - 33011825

SN - 0031-6970

VL - 77

SP - 435

EP - 437

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

IS - 3

ER -

Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19

UN SDGs

Access to Document

Other files and links

Cite this